Brain-scan neurofeedback training for voices heard in schizophrenia
Tests brain-scan neurofeedback training for hearing voices in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: DecNef for Auditory Verbal Hallucinations (AVH) in Schizophrenia
Key facts
- Where
- New York, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07779226, who can take part
Where in United States
- Columbia University Irving Medical CenterNew York, United StatesNo longer taking part
- New York State Psychiatric InstituteNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Columbia University
- Trial code
- NCT07779226
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to learn whether a research neurofeedback training approach done during MRI scans may help reduce hallucinations such as the experience of hearing voices persistent despite treatment.Read full original descriptionShow less
Decoded fMRI Neurofeedback for Auditory Verbal Hallucinations in Schizophrenia
The purpose of this study is to learn whether a research neurofeedback training approach done during MRI scans may help reduce hallucinations such as the experience of hearing voices persistent despite treatment.
Inclusion: Individuals aged 18 to 55, inclusive at screen; Capable of understanding the study procedures and willing and able to provide informed consent; Diagnosed with schizophrenia or schizoaffective disorder; Taking an antipsychotic medication at a stable dose for at least 4 weeks. All oral and depot antipsychotics are allowable; Mean Auditory Hallucination Rating Scale (AHRS) score >2 (moderate) and AHRS Frequency ≥ 4 (hourly AVH: Frequent at least 3 to 6 per hour); Meeting the decoder performance criterion, operationalized as ≥ 55% decoding accuracy. Baseline MRI may be repeated once for subthreshold decoder-accuracy at the discretion of the PIs; Normal hearing, operationalized as normal conversational hearing; Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for persons of childbearing potential only, unless post-menopausal or surgically sterile).
Exclusion: Diagnosis of moderate or severe substance use disorder (excluding nicotine) within the previous 90 days; Participation in study of investigational medication/device within the past 4 weeks; Contraindication to MRI scanning, including metal implants or clinically meaningful claustrophobia; Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 3 months prior to screening or participants who represent a significant risk of suicide or violence in the opinion of the investigator; Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety during study, including history of seizure, epilepsy in self or first degree relatives, stroke, brain surgery, head injury with loss of consciousness > 1 hour or clear cognitive sequelae, intracranial metal implants, known structural brain lesions; History of significant violent behavior in the past 3 months, posing a risk of homicide or having symptoms that would be exacerbated by study participation or travel to the site in the opinion of the investigator; Positive toxicology screen for any substances of abuse; Pregnant persons. Persons of child-bearing potential must have a negative urine β-hCG pregnancy test at Visit 1 and Visit 1a (if applicable).